366 related articles for article (PubMed ID: 34101869)
21. YAP/TAZ are Activated by Mechanical and Hormonal Stimuli in Myometrium and Exhibit Increased Baseline Activation in Uterine Fibroids.
Purdy MP; Ducharme M; Haak AJ; Ravix J; Tan Q; Sicard D; Prakash YS; Tschumperlin DJ; Stewart EA
Reprod Sci; 2020 Apr; 27(4):1074-1085. PubMed ID: 32056132
[TBL] [Abstract][Full Text] [Related]
22. SEPTIN10-mediated crosstalk between cytoskeletal networks controls mechanotransduction and oncogenic YAP/TAZ signaling.
Weiler SME; Bissinger M; Rose F; von Bubnoff F; Lutz T; Ori A; Schirmacher P; Breuhahn K
Cancer Lett; 2024 Mar; 584():216637. PubMed ID: 38242197
[TBL] [Abstract][Full Text] [Related]
23. Regulation of cellular quiescence by YAP/TAZ and Cyclin E1 in colon cancer cells: Implication in chemoresistance and cancer relapse.
Corvaisier M; Bauzone M; Corfiotti F; Renaud F; El Amrani M; Monté D; Truant S; Leteurtre E; Formstecher P; Van Seuningen I; Gespach C; Huet G
Oncotarget; 2016 Aug; 7(35):56699-56712. PubMed ID: 27527859
[TBL] [Abstract][Full Text] [Related]
24. Signaling by the tyrosine kinase Yes promotes liver cancer development.
Guégan JP; Lapouge M; Voisin L; Saba-El-Leil MK; Tanguay PL; Lévesque K; Brégeon J; Mes-Masson AM; Lamarre D; Haibe-Kains B; Trinh VQ; Soucy G; Bilodeau M; Meloche S
Sci Signal; 2022 Jan; 15(717):eabj4743. PubMed ID: 35041461
[TBL] [Abstract][Full Text] [Related]
25. Complex roles of Hippo-YAP/TAZ signaling in hepatocellular carcinoma.
Shi H; Zou Y; Zhong W; Li Z; Wang X; Yin Y; Li D; Liu Y; Li M
J Cancer Res Clin Oncol; 2023 Nov; 149(16):15311-15322. PubMed ID: 37608027
[TBL] [Abstract][Full Text] [Related]
26. Activated TAZ induces liver cancer in collaboration with EGFR/HER2 signaling pathways.
Moon H; Park H; Chae MJ; Choi HJ; Kim DY; Ro SW
BMC Cancer; 2022 Apr; 22(1):423. PubMed ID: 35439973
[TBL] [Abstract][Full Text] [Related]
27. Lipophilic statins inhibit YAP coactivator transcriptional activity in HCC cells through Rho-mediated modulation of actin cytoskeleton.
Benhammou JN; Qiao B; Ko A; Sinnett-Smith J; Pisegna JR; Rozengurt E
Am J Physiol Gastrointest Liver Physiol; 2023 Sep; 325(3):G239-G250. PubMed ID: 37366601
[TBL] [Abstract][Full Text] [Related]
28. PDE4D binds and interacts with YAP to cooperatively promote HCC progression.
Ren H; Chen Y; Ao Z; Cheng Q; Yang X; Tao H; Zhao L; Shen A; Li P; Fu Q
Cancer Lett; 2022 Aug; 541():215749. PubMed ID: 35597479
[TBL] [Abstract][Full Text] [Related]
29. Hippo signaling pathway in companion animal diseases, an under investigated signaling cascade.
Budel SJ; Penning MM; Penning LC
Vet Q; 2021 Dec; 41(1):172-180. PubMed ID: 33945400
[TBL] [Abstract][Full Text] [Related]
30. USP10 Promotes Proliferation of Hepatocellular Carcinoma by Deubiquitinating and Stabilizing YAP/TAZ.
Zhu H; Yan F; Yuan T; Qian M; Zhou T; Dai X; Cao J; Ying M; Dong X; He Q; Yang B
Cancer Res; 2020 Jun; 80(11):2204-2216. PubMed ID: 32217697
[TBL] [Abstract][Full Text] [Related]
31. Fingolimod exerts
Du J; Qian M; Yuan T; Zhang B; Chen X; An N; He Q; Yang B; Ye S; Zhu H
Acta Pharm; 2022 Sep; 72(3):427-436. PubMed ID: 36651547
[TBL] [Abstract][Full Text] [Related]
32. 4-Acetylantrocamol LT3, a New Ubiquinone from
Chen YL; Yen IC; Lin KT; Lai FY; Lee SY
Am J Chin Med; 2020; 48(5):1243-1261. PubMed ID: 32668963
[TBL] [Abstract][Full Text] [Related]
33. A Critical YAP in Malignancy of HCC Is Regulated by Evodiamine.
Yun UJ; Bae SJ; Song YR; Kim YW
Int J Mol Sci; 2022 Feb; 23(3):. PubMed ID: 35163776
[TBL] [Abstract][Full Text] [Related]
34. Yes-associated protein up-regulates Jagged-1 and activates the Notch pathway in human hepatocellular carcinoma.
Tschaharganeh DF; Chen X; Latzko P; Malz M; Gaida MM; Felix K; Ladu S; Singer S; Pinna F; Gretz N; Sticht C; Tomasi ML; Delogu S; Evert M; Fan B; Ribback S; Jiang L; Brozzetti S; Bergmann F; Dombrowski F; Schirmacher P; Calvisi DF; Breuhahn K
Gastroenterology; 2013 Jun; 144(7):1530-1542.e12. PubMed ID: 23419361
[TBL] [Abstract][Full Text] [Related]
35. TBX3 functions as a tumor suppressor downstream of activated CTNNB1 mutants during hepatocarcinogenesis.
Liang B; Zhou Y; Qian M; Xu M; Wang J; Zhang Y; Song X; Wang H; Lin S; Ren C; Monga SP; Wang B; Evert M; Chen Y; Chen X; Huang Z; Calvisi DF; Chen X
J Hepatol; 2021 Jul; 75(1):120-131. PubMed ID: 33577921
[TBL] [Abstract][Full Text] [Related]
36. YAP/TAZ: Key Players for Rheumatoid Arthritis Severity by Driving Fibroblast Like Synoviocytes Phenotype and Fibro-Inflammatory Response.
Caire R; Audoux E; Courbon G; Michaud E; Petit C; Dalix E; Chafchafi M; Thomas M; Vanden-Bossche A; Navarro L; Linossier MT; Peyroche S; Guignandon A; Vico L; Paul S; Marotte H
Front Immunol; 2021; 12():791907. PubMed ID: 34956224
[TBL] [Abstract][Full Text] [Related]
37. SETD1A augments sorafenib primary resistance via activating YAP in hepatocellular carcinoma.
Wu J; Chai H; Li F; Ren Q; Gu Y
Life Sci; 2020 Nov; 260():118406. PubMed ID: 32918976
[TBL] [Abstract][Full Text] [Related]
38. Co-activation of PIK3CA and Yap promotes development of hepatocellular and cholangiocellular tumors in mouse and human liver.
Li X; Tao J; Cigliano A; Sini M; Calderaro J; Azoulay D; Wang C; Liu Y; Jiang L; Evert K; Demartis MI; Ribback S; Utpatel K; Dombrowski F; Evert M; Calvisi DF; Chen X
Oncotarget; 2015 Apr; 6(12):10102-15. PubMed ID: 25826091
[TBL] [Abstract][Full Text] [Related]
39. Increased expression of yes-associated protein/YAP and transcriptional coactivator with PDZ-binding motif/TAZ activates intestinal fibroblasts to promote intestinal obstruction in Crohn's disease.
Ou W; Xu W; Liu F; Guo Y; Huang Z; Feng T; Liu CY; Du P
EBioMedicine; 2021 Jul; 69():103452. PubMed ID: 34186485
[TBL] [Abstract][Full Text] [Related]
40. Suppression of YAP/TAZ-Notch1-NICD axis by bromodomain and extraterminal protein inhibition impairs liver regeneration.
Liu C; Cheng X; Chen J; Wang Y; Wu X; Tian R; Liu B; Ding X; Sun Q; Gong W
Theranostics; 2019; 9(13):3840-3852. PubMed ID: 31281517
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
